194 related articles for article (PubMed ID: 1586721)
1. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
[TBL] [Abstract][Full Text] [Related]
2. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
4. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
5. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
6. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
7. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
[TBL] [Abstract][Full Text] [Related]
8. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
10. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
11. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
12. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
[TBL] [Abstract][Full Text] [Related]
14. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
[TBL] [Abstract][Full Text] [Related]
15. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
16. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
18. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.
Diav-Citrin O; Atanackovic G; Koren G
Ther Drug Monit; 1999 Feb; 21(1):74-81. PubMed ID: 10051057
[TBL] [Abstract][Full Text] [Related]
19. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
